Corcept Therapeutics

Corcept Therapeutics

CORT· Manufacturing· Market cap · Fiscal year ends in December

CEO pay in FY2025Stock -30.9% in FY2025

Joseph K. Belanoff, M.D. is the CEO of Corcept Therapeutics and was paid $15.3M in FY2025 (Dec), up 55%.

Pay$100 in the stock at the end of FY20 → $133
CEO pay is from each Corcept Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Joseph K. Belanoff, M.D.FY2025
  2. 2Charles RobbFY2025
  3. 3William Guyer, Pharm.D.FY2025
  4. 4Sean MaduckFY2025
  5. 5Atabak MokariFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Corcept Therapeutics paid its 5 named executives $40.4M in total in FY2025 (Dec). CEO Joseph K. Belanoff, M.D. was paid $15.3M of that.

Name
Joseph K. Belanoff, M.D.Chief Executive Officer and President
Charles RobbChief Business Officer and Secretary
William Guyer, Pharm.D.Chief Development Officer
Sean MaduckPresident Corcept Endocrinology
Atabak MokariChief Financial Officer and Treasurer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Corcept Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board4

See all
  • David L. MahoneyDirector · 21 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
  • Kimberly ParkDirector · 6 yr on the boardIndependentAudit, Corporate Governance and Nominating (Chair)—Paid as an executive
  • Gregg AltonDirector · 5 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
  • Joshua M. MurrayDirector · 4 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Corcept Therapeutics Division head pay rose 56% to $6.2M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Corcept Therapeutics Division head pay rose 59% to $6.3M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Corcept Therapeutics CEO pay rose 55% to $15.3M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Corcept Therapeutics Division head pay rose 54% to $6.4M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Corcept Therapeutics CFO pay rose 59% to $6.1M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Corcept Therapeutics Division head pay fell 18% to $3.7M. The stock rose 3% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Corcept Therapeutics Division head pay rose 86% to $3.9M. The stock rose 60% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Corcept Therapeutics Division head pay fell 68% to $2.1M. The stock rose 3% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Corcept Therapeutics CEO pay rose 27% to $9.3M. The stock rose 60% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Corcept Therapeutics CEO pay fell 33% to $7.4M. The stock rose 3% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Corcept Therapeutics Division head pay rose 24% to $4.0M. The stock rose 60% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Corcept Therapeutics Division head pay fell 39% to $3.2M. The stock rose 3% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Corcept Therapeutics CFO pay rose 97% to $3.7M. The stock rose 60% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Corcept Therapeutics CFO pay fell 73% to $1.9M. The stock rose 3% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 17, 2026FY2025
Annual report10-KFeb 24, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AApr 10, 2024FY2023
Annual report10-KFeb 15, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data